Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
8.20
+0.25 (3.14%)
At close: Mar 11, 2025, 4:00 PM
7.26
-0.94 (-11.45%)
Pre-market: Mar 12, 2025, 4:07 AM EST
Stoke Therapeutics Employees
Stoke Therapeutics had 110 employees as of December 31, 2023. The number of employees decreased by 7 or -5.98% compared to the previous year.
Employees
110
Change (1Y)
-7
Growth (1Y)
-5.98%
Revenue / Employee
$152,209
Profits / Employee
-$958,700
Market Cap
434.33M
Employees Chart
STOK News
- 13 days ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in March - Business Wire
- 21 days ago - Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - Market Watch
- 21 days ago - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Business Wire
- 23 days ago - Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha
- 2 months ago - Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
- 2 months ago - Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire
- 3 months ago - Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire